TICKERNERD
Menu
ACETACETHealthcare · Biotechnology

ACET Stock Forecast: Adicet Bio, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$9.52
−0.10% on the day

The 6 Wall Street analysts covering Adicet Bio, Inc. hold a median 12-month price target of $23 — +136.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 10 Sept 2026 — in the lower half.

Market cap
$89.2M
Ticker Nerd rank
43 / 100
Median analyst target
$23
Analysts covering
6
Revenue$0.0
Operating income−$22.3M
Net income−$21.4M
Free cash flow−$20.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.0%
1M
+15.7%
YTD
+13.1%
1Y
−32.5%
From 52W high
−42.8%
From 52W low
+55.8%
$6
$17
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ACET stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Adicet Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 10 Sept 2026
43 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
78
Size
76
Growth
66
Revisions
56
Issuance
43
Volatility
42
Momentum
36
Quality
35
Value
7

Accruals (78): Reported profit is backed by cash, and the company is not expanding recklessly.

Value (7): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ACET stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ACET, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80$100Oct 25Jan 26Apr 26Jul 26ACETHigh $90Median $23Low $18

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $18Median $23High $90

The green dot is the last close — the median target sits +136.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
6 Aug 2026GuggenheimMaintainsBuy$100 → $90
5 May 2026JefferiesAssumesBuy$8.00 → $19
23 Mar 2026HC Wainwright & Co.MaintainsBuy—
13 Mar 2026GuggenheimMaintainsBuy—
21 Jan 2026HC Wainwright & Co.MaintainsBuy—
6 Jan 2026Canaccord GenuityMaintainsBuy—
7 Nov 2025HC Wainwright & Co.MaintainsBuy—
8 Oct 2025GuggenheimMaintainsBuy—
19 Sept 2025GuggenheimReiteratesBuy—
23 July 2025HC Wainwright & Co.AssumesBuy$4.00
21 Mar 2025GuggenheimReiteratesBuy—
7 Mar 2025Citizens Capital MarketsReiteratesMarket Perform—
7 Mar 2025HC Wainwright & Co.ReiteratesNeutral—
27 Feb 2025HC Wainwright & Co.ReiteratesNeutral—
6 Feb 2025JMP SecuritiesReiteratesMarket Perform—
5 Feb 2025HC Wainwright & Co.ReiteratesNeutral—
19 Dec 2024HC Wainwright & Co.ReiteratesNeutral—
18 Nov 2024HC Wainwright & Co.ReiteratesNeutral—
16 Oct 2024HC Wainwright & Co.ReiteratesNeutral—
30 Sept 2024HC Wainwright & Co.ReiteratesNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ACET appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ACET vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Adicet Bio, Inc. returned −32.5% against +17.5% for the S&P 500, dividends included.

ACET vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Oct 25Jan 26Apr 26Jul 26ACETS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ACET analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Adicet Bio, Inc. (ACET) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.6×

Cheaper than 80% of US stocks

Price / sales
—
Price / book
0.9×

Cheaper than 77% of US stocks

EV / EBITDA
0.0×

Cheaper than 60% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−78.1%

Higher than 16% of US stocks

Return on assets
−41.7%

Higher than 10% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Adicet Bio, Inc. (ACET) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Adicet Bio, Inc. has a market value of $89.2M and an enterprise value of −$2.6M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$99.0M.

  • Diluted earnings per share, trailing twelve months: $−11.45.

  • Free cash flow in the twelve months to 30 June 2026: −$85.0M.

  • Shares outstanding: 9.4M.

  • Trailing P/E: −0.6×; forward P/E: −2.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Adicet Bio, Inc. employs 102 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 11 Sept 2026

Data provided by Twelve Data

Peers

ACET vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ACETAdicet Bio, Inc.$89.2M
43
NTHINeOnc Technologies Holdings, Inc.$91.2M
20
ANIXAnixa Biosciences, Inc.$92.2M
64
ICCCImmuCell Corp.$89.7M
94
CGTXCognition Therapeutics, Inc.$93.2M
39
CRDFCardiff Oncology, Inc.$93.3M
44
RLYBRallybio Corp.$88.4M
54

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Adicet Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ACET news & analysis

Wall Street Analysts See a 258.21% Upside in Adicet Bio (ACET): Can the Stock Really Move This High?

Zacks Investment Research · 3 Sept 2026positive

Wall Street analysts' average price target for Adicet Bio (ACET) suggests a potential upside of 258.2%. The report notes that while the reliability of this metric is questionable, the positive trend in earnings estimate revisions could support upward movement in the stock.

Why it matters — ACET watchers would be interested because analyst price targets and favorable earnings estimate revisions signal perceived upside potential for the company.

Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?

Zacks Investment Research · 3 Sept 2026neutral

Zacks Investment Research compared the year-to-date performance of Adicet Bio (ACET) and Centene (CNC) relative to their respective sectors.

Why it matters — ACET watchers would care because the piece directly addresses how the stock is tracking against its industry peers and the broader medical sector.

Adicet Bio to Participate in Fireside Chat at H.C. Wainwright 28th Annual Global Investment Conference

Business Wire · 2 Sept 2026neutral

Adicet Bio announced that its President and CEO, Chen Schor, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 14-16, 2026, in New York. The announcement was made via Business Wire.

Why it matters — ACET watchers would care because the CEO's participation offers the company an opportunity to present its clinical-stage CAR-T pipeline to the investment community, increasing visibility at a major investor conference.

Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Update

Business Wire · 1 Sept 2026positive

Adicet Bio announced completion of the last patient visit for the planned Phase 1 safety and efficacy analysis of prula-cel (formerly ADI-001) in patients with systemic lupus erythematosus with or without lupus nephritis, and provided a corporate update.

Why it matters — Completing the last patient visit brings Adicet closer to reporting Phase 1 results for its lead CAR-T candidate in SLE, a key clinical milestone for the company.

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Business Wire · 31 Aug 2026neutral

Adicet Bio, Inc. announced it granted an inducement award on August 31, 2026, to an individual hired in August 2026. The new hire received non-qualified stock options to purchase 1,500 shares of Adicet's common stock under Nasdaq Listing Rule 5635(c)(4).

Why it matters — This disclosure is a routine corporate governance and compensation action, letting ACET watchers track new-hire equity grants that may affect share dilution.

FAQ

Frequently asked questions about ACET stock

What is the ACET stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Adicet Bio, Inc. have a median 12-month price target of $23, with estimates ranging from $18 to $90. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ACET stock a buy right now?

Of the 6 analysts covering Adicet Bio, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Adicet Bio, Inc. 43 out of 100 across roughly 4,600 US stocks as at 10 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ACET?

As at 10 Sept 2026, Adicet Bio, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (78 of 100).

Will ACET stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +136.3% from the last close, and Ticker Nerd's factor model ranks Adicet Bio, Inc. 43 out of 100 as at 10 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ACET stock forecast for 2030?

No analyst covering Adicet Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACET are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $90 over the next 12 months.

How has ACET stock performed over the past year?

Adicet Bio, Inc. returned -32.5% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Adicet Bio, Inc. do?

Adicet Bio, Inc. Common Stock is the equity of Adicet Bio, a clinical-stage biotechnology company focused on developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer.

What is the latest news on ACET?

The most recent item we track (Zacks Investment Research, 3 Sept 2026): "Wall Street Analysts See a 258.21% Upside in Adicet Bio (ACET): Can the Stock Really Move This High?". Wall Street analysts' average price target for Adicet Bio (ACET) suggests a potential upside of 258.2%. The report notes that while the reliability of this metric is questionable, the positive trend in earnings estimate revisions could support upward movement in the stock.

Company

About Adicet Bio, Inc.

Adicet Bio, Inc. Common Stock is the equity of Adicet Bio, a clinical-stage biotechnology company focused on developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company’s current pipeline centers on engineered, off-the-shelf cell therapies designed to target specific disease markers through chimeric antigen receptors, with lead programs such as prulacabtagene leucel and ADI-212 addressing autoimmune and oncology indications. Adicet Bio’s research and development efforts are aimed at advancing differentiated cell therapy candidates that combine immune-cell engineering with tumor-targeting or disease-modifying mechanisms. The company operates within the biotechnology and health technology sectors, where its programs contribute to the broader development of next-generation immunotherapies for patients with serious and difficult-to-treat conditions. Adicet Bio is headquartered in Boston, Massachusetts.

CEO Mr. Chen Schor BA, CPA, M.B.A. · 102 employees · United States · https://www.adicetbio.com